Nautilus Biotechnology (NASDAQ:NAUT) Sets New 12-Month High – Time to Buy?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $4.24 and last traded at $4.0440, with a volume of 119801 shares traded. The stock had previously closed at $3.95.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NAUT shares. Guggenheim boosted their price target on Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Stock Performance

The company has a market capitalization of $512.06 million, a P/E ratio of -8.61 and a beta of 1.45. The company’s fifty day simple moving average is $2.39 and its 200-day simple moving average is $1.83.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, sell-side analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Insider Transactions at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 25,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Wednesday, March 4th. The stock was bought at an average price of $2.61 per share, with a total value of $65,250.00. Following the completion of the purchase, the chief executive officer directly owned 10,366,721 shares of the company’s stock, valued at approximately $27,057,141.81. This represents a 0.24% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 41.10% of the stock is currently owned by insiders.

Institutional Trading of Nautilus Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC increased its holdings in shares of Nautilus Biotechnology by 19.6% in the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after acquiring an additional 3,849 shares during the period. Bridgeway Capital Management LLC boosted its position in Nautilus Biotechnology by 4.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after purchasing an additional 5,000 shares in the last quarter. Geode Capital Management LLC boosted its position in Nautilus Biotechnology by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after purchasing an additional 7,307 shares in the last quarter. Bank of America Corp DE grew its stake in Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after purchasing an additional 13,363 shares during the last quarter. Finally, Garde Capital Inc. purchased a new position in Nautilus Biotechnology in the fourth quarter valued at about $35,000. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.